• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 20-Nov-2017
SENSEX
33,360.37
17.57 (0.05%)
NIFTY
10,267.50
-16.10 (-0.16%)
EQUITY
    No Companies Visited

Back to news list
  • Dr Reddy's Lab bounces back after reporting Q2 results

    Dr Reddy's Laboratories was up 1.77% to Rs 2,489.95 at 11:52 IST, with the stock bouncing back from intraday low after the company announced Q2 September 2017 results during market hours today, 31 October 2017.

    Meanwhile, the S&P BSE Sensex was down 32.12 points or 0.1% at 33,234.04.

    On the BSE, 1.66 lakh shares were traded on the counter so far as against the average daily volumes of 46,000 shares in the past two weeks. The stock had hit a high of Rs 2,492 and a low of Rs 2,390.50 so far during the day.

    On a consolidated basis, Dr Reddy's Laboratories' (DRL) net profit fell 3.42% to Rs 284.90 crore on 1.1% decline in revenue to Rs 3546 crore in Q2 September 2017 over Q2 September 2016.

    The company's consolidated earnings before interest, tax, depreciation and amortization (EBITDA) grew by 7.28% to Rs 688.80 crore in Q2 September 2017 over Q2 September 2016. EBITDA margin improved to 19.4% in Q2 September 2017, from 17.9% in Q2 September 2016.

    G.V. Prasad, CEO and Co-Chairman of DRL said that healthy performance in India, emerging markets, Europe and PSAI businesses as well as continued focus on cost control, have contributed to sequential growth in the company's top line as well as bottom line, with an EBITDA increase of 105% over the previous quarter. Looking ahead, DRL expects to see results from products launched in the US during the first half of this fiscal.

    DRL will continue to focus on the launching of new products as well as on improving operational efficiencies and quality management systems across the company, Prasad said.

    Dr Reddy's Laboratories is an integrated global pharmaceutical company.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Since 1986, Capital Market Publishers India Pvt Ltd is undertaking equity research, publishing an investment fortnightly magazine, data-vending and software production. Analysts track industry, companies and the economy. Branches in the metros and major cities ensure comprehensive coverage.

The major strength is equity research. Stock-picking for investor’s portfolio is preceded by rigorous research. The advisory services are transmitted through Capital Market magazine, newsletters, Telefolio. Almost 85% of the scrip’s recommended by us show appreciation. On an average we outperform the Bombay Stock Exchange Sensitive Index twice over, and sometime three times. Our independent status insulates us from influence from brokers and other market participants, ensuring that the selection of stocks and research are unbiased.

We are also pioneers in corporate databases - Capitaline, Mutual Fund database - Navindia

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
91-22-25230011
For Capital Market Magazine Print Edition queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 20-Nov-2017
  •  ( 09:15) Indices edge lower in early trade  
  •  ( 08:44) Most Asian stocks decline  
Show News
20 November 2017 09:27
404.30
(0.89 %)
1166.75
(-0.37 %)
544.00
(0.39 %)
3227.00
(0.47 %)
492.10
(-0.29 %)
600.75
(-1.30 %)
273.00
(0.05 %)
2325.00
(0.00 %)
1699.00
(-0.12 %)
1834.00
(0.38 %)
3636.45
(0.05 %)
1270.95
(-0.60 %)
321.85
(-1.00 %)
964.10
(-0.71 %)
258.05
(0.19 %)
1022.20
(-0.18 %)
1243.95
(1.86 %)
826.70
(-0.33 %)
1409.50
(-0.50 %)
8425.00
(1.01 %)
179.15
(0.96 %)
179.00
(0.85 %)
209.00
(0.22 %)
906.25
(-0.38 %)
335.60
(-0.53 %)
517.90
(0.16 %)
423.85
(0.57 %)
243.25
(1.02 %)
697.70
(-0.52 %)
2713.00
(0.11 %)
294.40
(-0.12 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.